In 54/64 subjects with nosocomial diarrhea, fecal calprotectin levels correlated with the results of stool samples tested for Clostridium difficile toxin gene by PCR. Fecal calprotectin levels can be used as an adjunctive measure to PCR to support the diagnosis of C. difficile infection.
no significant differences in gender (53% male) and age distribution between the 2 groups; 47 (73%) individuals were Ն60 years old. CD-PCR ϩ cases had a higher mean white cell count (11.86 ϫ 10 9 Ϯ 7.23 ϫ 10 9 versus 8.15 ϫ 10 9 Ϯ 3.89 ϫ 10 9 cells/liter; P Ͻ 0.01) but did not differ significantly from CD-PCR Ϫ cases with regard to serum albumin level, serum creatinine level, temperature, ATLAS score (3), presence of abdominal pain, presence of IBD, or concomitant antibiotic therapy for Ն1 day during CDI therapy. The presence of diarrhea, assessed by documentation in medical charts, was more frequently reported in CD-PCR ϩ patients (93.2% in CD-PCR ϩ versus 70% in CD-PCR Ϫ patients; P ϭ 0.02). When clinically indicated, concurrent analyses for alternative infectious causes of diarrhea were negative. Among the 44 CD-PCR ϩ subjects, 2 (4.5%) suffered CDI complications, and 2 (4.5%) other patients died within 30 days from non-CDI-related causes.
CD-PCR ϩ patients had higher (P Ͻ 0.001) median (interquartile range) HR-fCPT values than CD-PCR Ϫ patients, at 983 g/g (351 to Ͼ1,800 g/g) compared with Ͻ100 g/g (Ͻ100 to 194 g/g) ( Fig. 1A) . Similarly, the median (interquartile range) LR-fCPT values were significantly higher (P Ͻ 0.001) in CD-PCR ϩ samples (Ͼ300 g/g [Ͼ300 to Ͼ300 g/g]) than in CD-PCR Ϫ samples (77.5 g/g [30 to 238 g/g]). However, the median sPCT levels in CD-PCR ϩ subjects did not significantly differ (P ϭ 0.08) from those in CD-PCR Ϫ subjects. The area under the curve (AUC) for HR-fCPT predicting CD-PCR positivity was 0.82 (95% confidence interval [CI], 0.70 to 0.94) with a sensitivity of 88.6% and a specificity of 75% at an HR-fCPT level of 135 g/g (Fig. 1B) , the threshold seen for an optimal AUC statistic. When using the manufacturer's suggested cutoff of 200 g/g for IBD interpreta-tion, the sensitivity decreased to 79.5% but maintained a 75% specificity. The LR-fCPT was less specific, with an AUC of 0.8 (95% CI, 0.67 to 0.92), sensitivity of 88.6%, and specificity of 55% at an LR-fCPT threshold of 81.5 g/g. The AUC for sPCT was not significant (0.64; 95% CI, 0.5 to 0.78) for predicting a CD-PCR ϩ result.
Within the CD-PCR ϩ group, the measured HR-fCPT level was greater than the cutoff of 135 g/g in 39/44 (88.6%) subjects and above the IBD threshold (200 g/g) in 35/44 (79.5%) subjects, compared to 5/20 (25%) subjects in the CD-PCR Ϫ group, regardless of the cutoff; statistical significance (P Ͻ 0.001) was maintained in both instances. Further analyses comparing the clinical and laboratory parameters of CD-PCR ϩ subjects with an HR-fCPT greater or less than either cutoff did not yield any significant parameters that could adjunctively support or refute a CDI diagnosis. The ATLAS score and its five components, analyzed independently, did not differ significantly between CD-PCR ϩ and CD-PCR Ϫ subjects and did not correlate with HR-fCPT and sPCT levels.
Our results are similar to those obtained in prior studies in which fCPT levels were found to correlate with the presence of C. difficile (4) (5) (6) . In one study, fCPT concentrations were found to be higher in CDI cases diagnosed by a toxin assay than those detected by PCR for the toxin gene (4), supporting the hypothesis that some proportion of CD-PCR ϩ samples represent colonization only (7, 8) .
We did not find that sPCT correlated with CD-PCR positivity. In a previous report (9) , sPCT correlated with CDI severity, but the cases were not stratified according to the diagnostic methods used (i.e., toxin enzyme immunoassay [EIA] versus PCR) (7, 8, 10) .
The principal limitations of our study are the small number of subjects enrolled, the inability to categorically discriminate between CDI and colonization, and the very small amount of CDIrelated complications preventing a correlation of fCPT and sPCT with CDI severity. Ideally, a cell cytotoxicity assay and toxigenic culture of the stool samples might have assisted in determining the presence of CDI versus colonization.
Our data suggest that HR-fCPT levels are elevated in a large proportion of CD-PCR ϩ individuals with nosocomial diarrhea, with lower levels in CD-PCR Ϫ patients, suggesting a possible adjuvant role for these levels in diagnosing CDI. Further studies in a larger number of patients are required to determine the performance and reliability of using HR-fCPT levels as an adjunct for diagnosis of CDI.
